Illustrative image – not actual.
GlaxoSmithKline is preparing to commence sale of USD 3.7 billion stake in Unilever’s listed India unit.
The company is planning to offload part or all of its 5.7 percent holding in Hindustan Unilever through a series of block trades, which could commence soon.
The company received the stake, valued at USD 3.7 billion, as part of the payment for the sale of a portfolio of assets that was completed in April 2020. However, no final decision has been taken on the timing of the proposed trades, and GlaxoSmithKline could decide to postpone the sale depending on market conditions and investor demand.
In December 2018, Unilever noted it would acquire the health food drinks brands of GlaxoSmithKline in India and Bangladesh and other markets for EUR 3.3 billion (USD 3.6 billion) in cash and shares in Hindustan Unilever. As part of the transaction, GlaxoSmithKline will receive 5.7 percent stake in the Indian unit.
